Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (JNJ – Research Report), Thermo Fisher (TMO – Research Report) and AbbVie (ABBV – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Johnson & Johnson (JNJ)
In a report released today, Morten Herholdt from HSBC maintained a Buy rating on Johnson & Johnson, with a price target of $240.00. The company’s shares closed last Thursday at $205.75.
According to TipRanks.com, Herholdt is a 3-star analyst with an average return of
Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $219.05, a 5.9% upside from current levels. In a report issued on January 5, Scotiabank also maintained a Buy rating on the stock with a $230.00 price target.
See the top stocks recommended by analysts >>
Thermo Fisher (TMO)
In a report released today, Sidharth Sahoo from HSBC reiterated a Buy rating on Thermo Fisher, with a price target of $670.00. The company’s shares closed last Thursday at $606.50, close to its 52-week high of $627.88.
Sahoo has an average return of
According to TipRanks.com, Sahoo is ranked #7168 out of 10401 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Thermo Fisher with a $652.39 average price target, which is a 6.5% upside from current levels. In a report issued on January 5, Citi also maintained a Buy rating on the stock with a $660.00 price target.
AbbVie (ABBV)
HSBC analyst Rajesh Kumar maintained a Buy rating on AbbVie today and set a price target of $265.00. The company’s shares closed last Thursday at $224.13.
According to TipRanks.com, Kumar is a 4-star analyst with an average return of
Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $254.35, which is a 10.0% upside from current levels. In a report issued on January 6, Berenberg Bank also maintained a Buy rating on the stock with a $270.00 price target.
